Publications by authors named "N Champtiaux"
Cytomegalovirus (CMV) ulcerations are rare clinical entities, but their occurrence is favored in immunocompromised patients who present a favorable environment for opportunistic infections. We describe the case of a patient treated for a systemic lupus erythematosus suffering from deep oral ulcerations. The case illustrates the complexity of establishing a precise etiological diagnosis of CMV lesions, as the diagnostic hypothesis can be varied: related to an immunodeficiency disorder or drug-induced toxidermia.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the connection between immune-checkpoint inhibitor (ICI)-associated myotoxicity, specifically looking at myocarditis and myositis, which can be life-threatening.
- It details a treatment strategy that involved the use of mechanical ventilation for respiratory muscle issues and the administration of the drugs abatacept and ruxolitinib in patients diagnosed with severe ICI myocarditis.
- Results showed a significant drop in myotoxicity-related fatalities from 60% in the initial patient group to just 3.4% in the later group, indicating the effectiveness of early intervention and specific treatment adjustments.
Objective: This study aimed to investigate the relationship between changes in clinical status on daily life physical activity (PA) in patients with idiopathic inflammatory myopathy (IIM).
Methods: Patients with dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) or overlap myositis (OM) who presented either a new-onset or relapsing IIM, stable disease on maintenance therapy or were undergoing immunosuppressant tapering were included. Patients were evaluated at inclusion (V0), and at two follow-up visits (V1, 94±12 days from V0; V2, 96±17 days from V1).
Introduction: IgA nephropathy (IgAN) can be associated with spondyloarthritis (SpA). The course of SpA-associated IgAN remains largely unknown due to the absence of large cohorts.
Methods: This retrospective study included patients with biopsy-proven IgAN and definite SpA.